ORNBV:OMXHEXOrion Oyj Class B Analysis
Data as of 2026-05-27 - not real-time
€71.68
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Technical outlook: Orion Oyj trades at €71.68, exactly at its identified resistance level, with a 20‑day SMA of €68.24 and a 200‑day SMA of €66.32 indicating an overall uptrend. However, the RSI sits at 74, flagging overbought conditions, while the MACD remains bullish. The stock’s beta is a modest 0.18, suggesting limited market‑wide volatility, yet the 30‑day volatility spikes at 27.5%.
Fundamental strength: The company posted 18% revenue growth, gross margins near 65%, and a remarkable ROE of 48%, far outpacing peers. At a forward‑looking P/E of 19 versus an industry average of 27, Orion appears relatively cheap, though its DCF‑derived fair value of €62 is below the current price, hinting at short‑term overvaluation. A 2.5% dividend yield with a 45% payout ratio, solid cash flow, and manageable debt further underpin its defensive profile.
Fundamental strength: The company posted 18% revenue growth, gross margins near 65%, and a remarkable ROE of 48%, far outpacing peers. At a forward‑looking P/E of 19 versus an industry average of 27, Orion appears relatively cheap, though its DCF‑derived fair value of €62 is below the current price, hinting at short‑term overvaluation. A 2.5% dividend yield with a 45% payout ratio, solid cash flow, and manageable debt further underpin its defensive profile.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- price perched at resistance €71.68
- RSI of 74 signals overbought conditions
- DCF fair value €62 indicates current overvaluation
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- robust 18% revenue growth and strong margins
- high ROE (48%) and solid cash generation
- stable dividend yield (2.5%) with sustainable payout
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- low beta (0.18) reduces market risk exposure
- pipeline of oncology and cardiovascular products
- healthy cash flow and low debt support dividend growth
Key Metrics & Analysis
Financial Health
Revenue Growth17.80%
Profit Margin27.11%
P/E Ratio19.1
ROE48.37%
ROA22.11%
Debt/Equity29.43
P/B Ratio9.0
Op. Cash Flow€276.4M
Free Cash Flow€328.3M
Industry P/E27.4
Technical Analysis
TrendNeutral
RSI74.1
Support€67.57
Resistance€71.68
MA 20€68.24
MA 50€69.25
MA 200€66.32
MACDBullish
VolumeStable
Fear & Greed Index91.29
Valuation
Fair Value€62.22
GradeOvervalued
TypeBlend
Dividend Yield2.51%
Risk Assessment
Beta0.18
Volatility27.52%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.